top of page

Search Results

Results found for "positive allosteric modulators"

  • Transformative GPCR Insights: Unleash New Horizons in Science | Sep 9 - 15, 2024

    Thal , et al., for their groundbreaking work on Positive allosteric modulation of a GPCR ternary complex 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗼𝗳 𝗔𝗘𝗙𝟬𝟭𝟭𝟳 𝗣𝗵𝗮𝘀𝗲 𝟮𝗯 𝗶𝗻 𝗖𝗨𝗗 Nxera Pharma’s Partner Centessa Announces Positive Senior Scientist/Staff Scientist, Computational Chemistry Postdoc in GPCR mechanosensing   Postdoctoral Position Postdoctoral research position Adhesion GPCRs Loss of cardiomyocyte-specific Adhesion G Protein Coupled allosteric modulation of a GPCR ternary complex GPCR Binders, Drugs, and more Progress on the development

  • Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism

    Ways Schild plots reveal hidden complexities like allosterism and receptor heterogeneity. Slopes <1  may reveal allosteric modulation , where the antagonist binds at a secondary site. When these same molecules act as antagonists, their curves shift not only in position but also in shape The model’s flexibility accommodates both agonism and antagonism as long as the analysis targets equilibrium Allosteric vs. orthosteric inhibition , distinguishable by the plateauing of effect.

  • Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc. has...

    Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Janssen Pharmaceuticals, Inc., ADX71149 is a selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator

  • Although the cannabinoid type-2 receptor (CB2) is highly expressed in the immune system, emerging...

    development of new CB2-related pharmacological and genetic tools, including the first small molecule positive allosteric modulator of CB2 receptors, has greatly advanced our understanding of this receptor. consequence of CB2 receptor activation could correct circuit-based deficits commonly associated with positive

  • Allosteric Effect of Nanobody Binding on Ligand-Specific Active States of the β2 Adrenergic Receptor

    Nanobody binding stabilizes G-protein-coupled receptors (GPCR) in a fully active state and modulates However, the atomic-level basis for this allosteric regulation remains elusive. In particular, we identify unique allosteric signal transmission mechanisms between the Nb80-binding site and the extracellular domains in conformations modulated by a full agonist, BI167107, and a G-protein-biased

  • Why Kinetics Matter More Than Kd in GPCR Drug Discovery

    Breakthroughs this week: Structure-based discovery of positive allosteric modulators of the A1 adenosine opportunities:  Principal Scientist - In Vitro Pharmacology; Senior Scientist, Molecular Pharmacology; PhD position Prevent wasted cycles:  Avoid costly delays caused by false positives from static affinity readouts. modulators to computational targeting—will take shape. Identify emerging targets:  Allosteric modulators, biased ligands, and kinetic frameworks will dominate

  • Adenosine receptor signalling in Alzheimer's disease

    receptors approved for treating dementia, we provide insights into some novel strategies, including allosterism

  • Adenosine receptor signalling in Alzheimer's disease

    receptors approved for treating dementia, we provide insights into some novel strategies, including allosterism

  • Irreversible Drugs, Real Control: Design for Durable Target Engagement

    Get Yearly Access On-Demand Now — Free 7 Day Trial ➤ DrGPCR Podcast: Jens Carlsson on Predictive Modeling Jens Carlsson shares how structure-based design, molecular dynamics, and smart collaboration turn models Ideal for scientists who want modeling to guide experiments, not just narrate them. Bridge the aisle —modelers × experimentalists for faster iteration. Listen to the episode ➤ Why Dr.

  • 📰 GPCR Weekly Buzz: Exciting Schedule Shifts for Principles of Pharmacology I & II | August 12-18, 2024

    modulators of the glucagon subfamily of GPCRs  Let’s dive into the   Classified GPCR News  from August heart rate in the Pacific abalone Haliotis discus hannai GPCR Binders, Drugs, and more Photo-BQCA: Positive Allosteric Modulators Enabling Optical Control of the M1 Receptor Isoquinoline small molecule ligands are agonists and probe-dependent allosteric modulators of the glucagon subfamily of GPCRs GPCRs in Cardiology Postdoctoral research position Senior or Lead Researcher   Senior Scientist, Cryo-Electron Microscopy

  • 📰 GPCR Weekly News

    Microenvironment Industry News Addex and Indivior Extend Research Term Of Substance Use Disorder Gabab Positive Allosteric Modulator Discovery Collaboration Domain Therapeutics strengthens Scientific Advisory Board

  • GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions

    Terry Kenakin reframes GPCRs as dynamic, allosteric sensors—far from static binding sites. Position your research for maximum visibility.   It’s the 20th anniversary—and the spotlight is squarely on kinetic modeling, allosteric frameworks, and Terry Kenakin on “The Kinetics of Allostery: The Added Benefits of Allosteric Function.” Access peer insights on allosteric modulators and biased ligands.

  • 📰 GPCR Weekly News, July 31 to August 6, 2023

    GPCR Symposium on 'GPCRs as Therapeutic Modalities' is set for September 22nd. Neuroscience Quinpirole ameliorates nigral dopaminergic neuron damage in Parkinson's disease mouse model Drosophila Smaug to the GPCR Smoothened and to the germline inducer Oskar Industry News Addex GABAb Positive Allosteric Modulator Program To Receive Additional Chf 2.7 Million From Indivior In Extended Substance Target - DOT (September 25 - 28, 2023) Training Seminar "The Renaissance in GPCRs as Drug Targets: Allosteric

  • Opioid Ligands Addressing Unconventional Binding Sites and More Than One Opioid Receptor Subtype

    most significant groups of G-protein coupled receptor (GPCR) drug targets and also act as prototypical models ligands (i. e. aiming on two distinct OR subtypes), univalent heteromer-selective ligands and bitopic and allosteric

  • 📰 GPCR Weekly News, March 4 to 10, 2024

    Activate G Protein-Coupled Receptors GPCRs in Neuroscience A M1 muscarinic acetylcholine receptor-specific positive allosteric modulator VU0486846 reduces neurogliosis in female Alzheimer's mice The association of GNB5 spectroscopy Up-regulation of GPR139 in the medial septum ameliorates cognitive impairment in two mouse models

  • 📰 GPCR Weekly News

    Biased agonists differentially modulate the receptor conformation ensembles in Angiotensin II type 1 Therapeutic potential of allosteric modulators for the treatment of gastrointestinal motility disorders Characterization of a novel positive allosteric modulator of the α1A-Adrenergic receptor. Lipid Modulation of a Class B GPCR: Elucidating the Modulatory Role of PI(4,5)P2 Lipids. Surveying nonvisual arrestins reveals allosteric interactions between functional sites.

  • 🤯Mind-blowing GPCR Scoops! Discover the Latest Breakthroughs! ⦿ Nov 18 - 24, 2024

    Alexander S Hauser GPCRdb in 2025: adding odorant receptors, data mapper, structure similarity search and models bitter anti-inflammatory drug binds at two distinct sites of a human bitter taste GPCR Photo-BQCA: Positive Allosteric Modulators Enabling Optical Control of the M1 Receptor The cell adhesion molecule CD44 acts as a modulator of 5-HT7 receptor functions Signal profiles and spatial regulation of β-arrestin recruitment pharmacogenomics research GPCRdb in 2025: adding odorant receptors, data mapper, structure similarity search and models

  • Therapeutic validation of an orphan G protein‐coupled receptor

    IM (3,3′‐methylenebis‐1H‐indole) has been identified as a positive allosteric modulator of GPR84, a metabolite

  • Therapeutic validation of an orphan G protein-coupled receptor: The case of GPR84

    August 2022 "Despite the importance of members of the GPCR superfamily as targets of a broad range of effective medicines many GPCRs remain poorly characterised. GPR84 is an example. Expression of GPR84 is strongly up regulated in immune cells in a range of pro-inflammatory settings and clinical trials to treat idiopathic pulmonary fibrosis are currently ongoing using ligands with differing levels of selectivity and affinity as GPR84 antagonists. Although blockade of GPR84 may potentially prove effective also in diseases associated with inflammation of the lower gut there is emerging interest in defining if agonists of GPR84 might find utility in conditions in which regulation of metabolism or energy sensing is compromised. Here, we consider the physiological and pathological expression profile of GPR84 and, in the absence of direct structural information, recent developments and use of GPR84 pharmacological tool compounds to study its broader role and biology. " Read more at the source #DrGPCR #GPCR #IndustryNews

  • GPCR Weekly Whirlwind: Top Receptor Highlights from Sep 30 - Oct 6, 2024!

    Modules: October 31st : The Eyes to See- The Importance of Pharmacologic Assays. Positive Feedback from Our Esteemed Students Past students highly recommend our programs, lauding the Postdoctoral research position GPCR Activation and Signaling Preassembly of specific Gβγ subunits at somatostatin receptors SSTR1 and SSTR3 SPMs exert anti-inflammatory and pro-resolving effects through positive allosteric modulation of the prostaglandin EP4 receptor GPCR Binders, Drugs, and more Molecular glues

  • Pharmacologic Models

    Terry Kenakin’s newest foundational lesson in Terry's Corner  cuts straight to it:   Why models are vital for translating lab data into clinical forecasts The 4 types of pharmacologic models (and when to use each) The truth about linear models: useful or misleading? How the Mass Action Law underpins nearly every model Future of Receptor Theory: Linkage vs. Unlock "Pharmacologic Models" now

  • From Multiplex to Models: Scaling Up GPCR Discovery in the Post-Silo Era

    Watch Episode 167 Today’s GPCR scientists don’t want to study one interaction, they want to model the visiting scientists are already expanding this work, bringing in computational layers  like AlphaFold to model

  • Mechanistic basis of GPCR activation explored by ensemble refinement of crystallographic structures

    October 2022 "G protein-coupled receptors (GPCRs) are important drug targets characterized by a canonical seven transmembrane (TM) helix architecture. Recent advances in X-ray crystallography and cryo-EM have resulted in a wealth of GPCR structures that have been used in drug design and formed the basis for mechanistic activation hypotheses. Here, ensemble refinement (ER) of crystallographic structures is applied to explore the impact of binding of agonists and antagonist/inverse agonists to selected structures of cannabinoid receptor 1 (CB1R), β2 adrenergic receptor (β2 AR) and A2A adenosine receptor (A2A AR). " Read more at the source #DrGPCR #GPCR #IndustryNews

  • GPCR Collaboration: From Models to Medicine

    Predictions from modeling inform chemistry. Chemistry fuels assays. Assay data flows back into models. The cycle only works because every part is connected .   His group is trained to explain exactly what a model can predict and where its limits are. Biased signaling, allosteric binding sites, and subtype selectivity mean there is rarely a straight line He treats modeling as part of a continuum rather than a separate discipline.

  • Functional modulation of PTH1R activation and signaling by RAMP2

    receptors (GPCRs), including the parathyroid hormone 1 receptor (PTH1R), a class B GPCR and an important modulator the activation of PTH1R and its downstream signaling, we describe here that RAMP2 acts as a specific allosteric modulator of PTH1R, shifting PTH1R to a unique preactivated state that permits faster activation in Moreover, RAMP2 modulates PTH1R downstream signaling in an agonist-dependent manner, most notably increasing of RAMPs in the activation and signaling of a GPCR that may provide a new venue for highly specific modulation

  • Molecular basis for ligand modulation of the cannabinoid CB 1 receptor

    improved our molecular understanding of CB1 ligand interactions, selectivity, receptor activation and allosteric modulation. In this review, we describe the structural determinants for modulation of CB1 receptors by different

  • Mechanism of enhanced sensitivity of mutated β-adrenergic-like octopamine receptor to amitraz in...

    October 2022 Mechanism of enhanced sensitivity of mutated β-adrenergic-like octopamine receptor to amitraz in honeybee Apis mellifera: An insight from MD simulations "Background: Amitraz is one of the critical acaricides/insecticides for effective control of pest infestation of Varroa destructor mite, a devastating parasite of Apis mellifera, because of its low toxicity to honeybees. Previous assays verified that a typical G protein-coupled receptor, β-adrenergic-like octopamine receptor (Octβ2R), is the unique target of amitraz, but the honeybee Octβ2R resists to amitraz. However, the underlying molecular mechanism of the enhanced sensitivity or toxicity of amitraz to mutated honeybee Octβ2RE208V/I335T/I350V is not fully understood. Here, molecular dynamics simulations are employed to explore the implied mechanism of the enhanced sensitivity to amitraz in mutant honeybee Octβ2R." Read more at the source #DrGPCR #GPCR #IndustryNews

  • Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine...

    December 2021 Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine 2022 SAN DIEGO, Dec. 7, 2021 /PRNewswire/ -- Neurocrine Biosciences (Nasdaq: NBIX) today announced positive

  • Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in...

    August 2022 Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in transformative medicines for people living with psychiatric and neurological conditions, today announced positive KarXT demonstrating a statistically significant and clinically meaningful 9.6-point reduction in the Positive

  • Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European ...

    November 2021 Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive

bottom of page